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Abstract: Radioiodine, antithyroid drugs and surgery have been well established therapies for 
Graves’ hyperthyroidism for several decades. However there remain large variations in practice 
among physicians in the preferred modality and the method of administration. Patient choice 
and perceptions also play a big role in the choice of treatment. Radioiodine may be given using 
fixed high doses or by calculated doses following uptake studies. The risks of radioiodine includ-
ing eye disease and the role of prophylactic steroid therapy are discussed. The commonly used 
antithyroid drugs include carbimazole, methimazole and propylthiouracil; however a number 
of other agents have been tried in special situations or in combination with these drugs. The 
antithyroid drugs may be given in high (using additional levothyroxine in a block–replace 
regimen) or low doses (in a titration regimen). This review examines the current evidence and 
relative benefits for these options as well as looking at emerging therapies including immuno-
modulatory treatments such as rituximab which have come into early clinical trials. The use 
of antithyroid therapies in special situations is also discussed as well as clinical practice issues 
which may influence the choices.
Keywords: Graves’ hyperthyroidism, radioiodine, antithyroid drugs, methimazole, propyl-
thiouracil
Introduction
Graves’ disease affects about 0.5% of the population, predominantly patients in the 
age group 40 to 60 years with a female to male ratio of 5:1 to 10:1. Circulating thyroid 
antibodies activate the thyroid stimulating hormone (TSH) receptor and stimulate 
thyroid follicular hypertrophy and hyperplasia with increases in thyroid hormone 
production.1 Graves’ ophthalmopathy occurs in a mild form in 25% to 50% of patients 
with Graves’ disease, with about 3% to 5% of patients having severe eye disease needing 
immunosuppression, orbital surgery or radiotherapy.2 If painless thyroiditis or toxic 
nodular goitre are diagnostic possibilities, a radionuclide uptake scan may be helpful to 
differentiate these conditions by showing increased uptake in Graves’ hyperthyroidism 
(GH), low uptake in thyroiditis and hot nodules in toxic nodular goitre. Despite the avail-
ability of the two most popular therapeutic choices (radioiodine [RAI] and antithyroid 
drugs) in GH for several decades, there remain several areas of uncertainty with large 
differences in opinion as to the preferred modality and mode of administration. This 
is reflected in the large variation in the first-line choices among different countries.3 
Radioiodine is used considerably more frequently in the US compared to Europe and 
parts of Asia. Surgery is less commonly used and is usually reserved for patients with 
large goitres, intolerance to antithyroid drugs and difficulties in administering RAI. Therapeutics and Clinical Risk Management 2010:6 30
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This review will focus on the antithyroid drugs and RAI and 
will also touch on some of the emerging therapies.
Antithyroid drugs
Thionamides are the most commonly used antithyroid medi-
cations and were introduced in 1943 by Astwood. Methima-
zole (MMI), carbimazole (CBZ), and propylthiouracil (PTU) 
are the mainstays of antithyroid-drug therapy. MMI is the 
active metabolite of CBZ, and since the conversion of CBZ 
to MMI in the body is virtually complete, their effects and 
equivalent doses are thought to be comparable. These drugs 
block the synthesis of thyroid hormone by the thyroid gland.4 
Their main effect is to inhibit thyroid hormone synthesis by 
interfering with thyroid peroxidase mediated iodination of 
tyrosine residues in thyroglobulin which is an important step 
in the synthesis of thyroxine (T4) and triiodothyronine (T3).5 
They may also help control the disease by indirectly affect-
ing the immune system. Various in vitro and in vivo studies 
have shown reductions in immune-related molecules such as 
intracellular adhesion molecule 1 and soluble interleukin 2 
as well as decreasing antithyrotropin receptor antibodies over 
time.6–8 How much of these immune related improvements are 
due to improvements in thyroid functions is still unclear. PTU 
also inhibits the peripheral conversion of T4 to T3 though the 
effect is not clinically important in most situations.
The choice of which drug is used may be dictated by 
availability. CBZ is the most commonly used drug in the 
UK. MMI and PTU are used in the USA and MMI is used 
more often in most of Europe and Asia.5 The serum half-life 
of MMI is 6 to 8 hours whereas the half life of PTU is 1 to 
2 hours. In addition MMI has been found to have measurable 
intrathyroidal concentrations up to 20 hours.9 Several studies 
have shown that MMI is effective when given in a once daily 
dose.10–12 PTU is not as effective in a single dose.13 The com-
pliance with more frequent dosing schedule of PTU was only 
53% compared to 83% with once daily MMI.11 These factors 
and the adverse effects profile of PTU have led to MMI/CBZ 
being the more popular first choice antithyroid drug.
Dose and regimen
The starting dose of CBZ/MMI is usually between 20 to 
40 mg/day depending on the severity of the hyperthyroidism. 
PTU is started at between 100 to 150 mg 3 times a day 
with 100 mg of PTU considered equal to about 10 mg of 
CBZ/MMI. The initial high dose of the drugs can be tapered 
down after 4 to 8 weeks in what is referred to as the titra-
tion regimen. A maintenance dose of 5 to 20 mg of MMI or 
equivalent is achieved by about 4 to 6 months and this is con-
tinued for 12 to 18 months. The block–replace regimen refers 
to the option of maintaining the high dose of antithyroid drugs 
while adding levothyroxine to maintain euthyroidism. This 
has the advantage of fewer thyroid function tests (TFTs) but 
there is some evidence of a higher frequency of side effects. 
About 12 trials14–25 (Table 1) have examined these regimens. 
The relapse rates are similar at over 55% but the withdrawal 
due to side effects (16% versus 9%) and complication rates 
Table 1 Studies comparing high dose vs low dose antithyroid drugs
Study Drug and dose  
in high-dose arma
Total no 
assessed
Relapse (%) Rash Withdrawal due  
to side effects
High Low High Low High Low
Benker14 MMi 40 mg 291 54% 58% 7% 6% 13% 7%
edmonds15 CBZ 60 mg 70 50% 67% 14% 11% 16% 13%
Goni iriarte16 CBZ 30 mg 63 61% 63%
Grebe17 CBZ 100 mg 25 66% 94% 29% 0% 41% 0.5%
Jorde18 MMi 60 mg 41 58% 77% 21% 7% 31% 15%
Leclere19 CBZ 60 mg 196 40% 47% 6% 0.8%
Lucas20 CBZ 60 mg 60 67% 60%
Mciver21 CBZ 40 mg 30 61% 47%
Nedrebo22 CBZ 40 mg 189 48% 45% 10% 9%
Rittmaster23 MMi 30 mg 145 58% 59%
Tuncel24 PTU/MMi? dose 73 15% 18%
wilson25 CBZ 60 mg 63 36% 57% 18% 7%
Total no 1246 51%b 54%b 9.8% 5.8% 16% 9%
aThe high dose arm added levothyroxine in a block–replace regimen while the dose was titrated down in the other arm.
bThere was a high loss to follow-up of 30% in these studies and the relapse rates assuming relapsed hyperthyroidism in all dropouts were between 63 to 68%.
Abbreviations: CBZ, carbimazole; MMi, methimazole; PTU, propylthiouracil.Therapeutics and Clinical Risk Management 2010:6 31
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including rashes and agranulocytosis were higher in the 
block–replace regimen.26 One trial that used CBZ 100 mg 
daily led to 7 out of 17 (46%) withdrawing from the high 
dose arm due to side effects and 2 cases (12%) had agranu-
locytosis, a potentially fatal complication.17
The addition of levothyroxine during low dose antithyroid 
drug therapy with continued levothyroxine alone showed 
promising results in one randomized trial,27 which was 
not confirmed in three subsequent trials28–30 or in a meta-
analysis.26 The final choice of regimen is determined by the 
physician’s preferences with the titration regimen being our 
preferred regimen. Whatever the choice, the reality is that 
close to 60% of patients will have a relapse and discussions 
should include the possibility of RAI or surgery as definitive 
options in the event of a relapse. Attempts at finding pre-
dictors for a relapse have met with variable success. Male 
sex, large goitres, a high FT3 level, smoking and high TSH 
receptor antibodies are potential relapse predictors and may 
also influence the choice. The majority of European patients 
choose antithyroid drugs for the initial therapy with a pro-
portion choosing further antithyroid medications or RAI for 
subsequent relapses.
Duration of therapy
The optimal duration of therapy is considered to be 12 to 
18 months.26 In one study31 the longer-duration titration 
regimen (18 months) had significantly fewer relapses (37%) 
than the 6-month group (58%). One study32 found there was 
no significant difference between 12 and 6 months using 
the block–replace regimen. Two other studies used longer 
durations of titration regimen, comparing 12 months with 
24 months33 and 18 months with 42 months of therapy.34 There 
was no additional benefit in these studies in continuing the 
antithyroid treatment beyond 18 months.
Clinical practice points
Our practice is to use a titration regimen with a starting 
dose of CBZ between 20 and 40 mg/day depending on the 
severity of the initial thyrotoxicosis (eg, if FT4  30: CBZ 
10 to 20 mg, and if FT4  40: CBZ: 40 mg, while also 
considering clinical factors of severity such as weight loss, 
cardiovascular involvement and duration of symptoms). We 
use betablockers for the initial 6 to 8 weeks if there are no 
contraindications. Thyroid functions are checked at 4 weeks 
(often by primary care saving a hospital visit) after initiation 
of CBZ and the dose of CBZ halved. Once a patient is on a 
maintenance dose of CBZ, TFTs are done every 2 to 4 months 
and the treatment continued for 12 to 18 months depending 
on the response. The patients are seen 4 to 6 monthly for 
1 year after completion of antithyroid therapy and subsequent 
annual TFTs are done in primary care.
Side effects of antithyroid medications
Side effects are encountered in about 5% of patients using 
antithyroid medications. The most common side effect 
reported is drug rash, which may be noted in as high as 10% 
of patients using higher doses.26 Other minor side effects 
include arthralgia, gastrointestinal complaints, and changes 
in taste and smell. The side effects of MMI appear to be dose 
related while the side effects of PTU are less clearly related to 
dose.5 Minor side effects may be self limiting or may resolve 
with the addition of an antihistamine or switching from one 
antithyroid agent to the other. However the cross reactivity 
between the agents may be as high as 50% and pursuing 
definitive therapy with RAI is the preferred option. Serious 
side effects that are potentially life threatening occur in about 
3 of 1000 patients. Agranulocytosis (absolute granulocyte 
count less than 500 per mL3) is the most serious and occurs 
with a frequency of about 0.35% with the elderly being 
potentially at a higher risk. Most cases occur in the first 
3 months; however, this can occur even a year or more after 
starting therapy and during renewed exposure when treating 
a relapse. Higher doses are associated with a greater risk and 
in one large series using routine monitoring of granulocyte 
counts, the incidence of agranulocytosis was 0.8% among 
2087 patients started on MMI 30 mg daily compared to 0.2% 
among 2739 patients started on MMI 15 mg daily.35 Routine 
monitoring of granulocyte count is generally regarded as 
unhelpful by most experts. Fever and sore throat are the 
most common presenting features of agranulocytosis and 
patients should receive verbal and written information about 
the importance of getting an urgent white cell count in these 
situations and confirming the absence of this complication for 
continued antithyroid drug therapy. If the granulocyte count 
is less than 1000/mL, the drug should be stopped. Treatment 
consists of the intravenous administration of antibiotics 
(including coverage for pseudomonas which is regarded as 
the most frequent infection) in patients who are febrile or 
have obvious infections. The administration of granulocyte 
colony-stimulating factor is considered to shorten the 
recovery time and length of hospitalization, though one pro-
spective randomized trial failed to confirm this.36 There is 
cross reactivity between PTU and MMI for agranulocytosis 
and further use of these agents is contraindicated.
Hepatotoxicity is rarer than agranulocytosis with a 
frequency of 0.1% to 0.2%.5 Asymptomatic elevation of Therapeutics and Clinical Risk Management 2010:6 32
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aminotransferases occurs in untreated hyperthyroid patients 
and during commencement of PTU and usually normalizes. 
Routine monitoring of liver functions is not recommended. 
PTU-related hepatotoxicity usually occurs after 3 months of 
therapy and takes the form of an allergic hepatitis with marked 
elevation of liver enzymes. A fatality rate of 25% to 50% 
has been reported though this may well be due to a reporting 
bias. Appropriate management of severe hepatic failure with 
specialist involvement is required. The hepatic toxicity of 
MMI is typical of a cholestatic process and generally recovers 
slowly following discontinuation of the therapy.
Vasculitis is another major side effect seen more com-
monly with PTU. Some patients especially Asians develop 
antineutrophil cytoplasmic antibody (ANCA) positive vas-
culitis with resultant renal failure, arthritis, vasculitic rash 
and respiratory symptoms. Steroids, cyclophosphamide and 
hemodialysis may be needed in some patients, while others 
improve on drug discontinuation. A cross sectional study in 
the UK showed that 33% of patients on PTU, 16% on CBZ 
and 30% of previously antithyroid drug-treated Graves’ 
patients had ANCA positivity compared to about 5% of 
euthyroid controls and untreated Graves’ patients.37 The 
clinical significance of these findings is not known.
Special situations
Pregnancy and lactation
Hyperthyroidism occurs in 0.1% to 0.2% of all pregnan-
cies. Untreated hyperthyroidism results in increased risk 
of pre-eclampsia, preterm delivery, low birth weight and 
increased neonatal mortality and morbidity. The mother 
is also at increased risk of heart failure, thyroid storm and 
pre-eclampsia. PTU is the preferred antithyroid agent dur-
ing pregnancy, as congenital anomalies such as aplasia cutis 
(single or multiple lesions of 0.5 to 3 cm at the vertex or 
occipital area in the scalp), choanal and esophageal atresia 
are reported more frequently with MMI.38 The incidence of 
these anomalies is quite rare and it is acceptable to continue 
MMI particularly in areas where PTU is not easily available. 
The PTU dose is reduced to the lowest effective dose to 
maintain the FT4 towards the upper end of the reference 
range with monthly monitoring of thyroid functions.39 
The activity levels of Graves’ disease may fluctuate during 
pregnancy, with exacerbation during the first trimester with 
improvement in later pregnancy with a higher chance of an 
exacerbation soon after delivery. Up to a third of patients 
may be able to discontinue the PTU during the later part of 
pregnancy. Thyroid functions need to be checked at 6 and 
12 weeks postpartum in anticipation of potential postpartum 
exacerbation of the GH. In patients who have adverse effects 
with antithyroid drugs or require persistently high doses, thy-
roid surgery may be considered during the second trimester. 
Thyroid receptor antibodies should be measured by the end 
of the second trimester in patients who have current Graves’ 
disease or have had previous ablation (RAI or surgery). 
Patients with elevated antibody levels need assessment for 
foetal and neonatal thyroid dysfunction. Foetal ultrasound 
features of thyroid dysfunction include growth restriction, 
advanced bone age, goitre or cardiac failure. Both PTU and 
MMI appear in low concentrations in the breast milk but do 
not influence the infant thyroid function and breast feeding 
is permitted on moderate doses of these agents.
Adolescence
It is not uncommon to continue the antithyroid medications 
beyond the usual 12 to 18 months during the critical years of 
the child’s education and examinations. An opportune timing 
is chosen mutually with the child and parents to withdraw 
the medication such that a recurrence in the first few months 
following withdrawal is least likely to cause a major disrup-
tion to studies and progress.
elderly
Longer-term low dose CBZ/MMI is acceptable in some 
elderly patients when other modalities of definite therapy 
such as RAI or surgery are less appropriate. The care needs 
of elderly patients may prevent the use of RAI due to the 
difficulty in administering this while minimizing contact 
with vulnerable carers. The risks of cardiac failure and 
atrial fibrillation with uncontrolled hyperthyroidism as well 
as the challenges of regular monitoring in this age group 
are additional considerations. No significant complications 
were noted in one study giving continuous low dose MMI 
for over 10 years.40
inability to take oral preparations
In patients unable to take antithyroid medications orally, rec-
tal and parenteral routes of administration have been reported 
though there are no commercially available formulations. 
One report used an enema formulation of PTU made of eight 
50 mg tablets dissolved in mineral oil.41 Another report used 
an enema preparation of PTU with sterile water administrated 
by means of a Foley catheter inserted into the rectum.42 MMI 
has also been administered rectally.43 One study compared 
the use of an enema preparation with water versus a supposi-
tory preparation with polyethylene glycol base and found 
comparable therapeutic effects.44Therapeutics and Clinical Risk Management 2010:6 33
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Atrial fibrillation
Atrial fibrillation due to hyperthyroidism is associated with 
increased risk of thromboembolism.45 Therefore in addition 
to rate control agents such as betablockers, anticoagulation 
with warfarin is highly recommended. Meticulous control 
of hyperthyroidism is best achieved initially with antithyroid 
drugs. Once hyperthyroidism is well controlled and rhythm 
stabilized, definitive therapy with RAI should be considered 
to eliminate hyperthyroidism permanently. Anitocoagulation 
may be affected by thyroid hormone status and methimazole, 
and therefore careful monitoring is essential. Anticoagula-
tion should be continued till hyperthyroidism is permanently 
eliminated and sinus rhythm is restored.
Radioiodine for GH
Radioiodine (RAI) emerged as a major treatment for hyper-
thyroidism after Hertz and Roberts successfully treated 
hyperthyroid patients with 131I in the US in 1941.46 Despite 
vast worldwide clinical experience for 6 decades, controver-
sies exist in almost every area of its use. Expert opinion is still 
divided on the timing of RAI,47 dosing of RAI, its long-term 
effects and the use of adjunctive antithyroid drugs.
Mechanism of action
After oral administration, RAI is absorbed and is incorporated 
in to thyroid. Continuous radiation to thyroid cells results in 
extensive local destruction and thyroid gland is ablated over 
a period of 6 to 18 weeks.48
RAi dosing
Low dose versus high dose RAi
Low dose RAI is aimed at curing hyperthyroidism without 
resulting in hypothyroidism. However, this approach results 
in higher treatment failures49 needing additional antithyroid 
drug treatment and further RAI doses.49,50 Although the 
incidence of hypothyroidism was low immediately after RAI 
with this approach, more than 50% of patients still developed 
hypothyroidism in the long term. On the contrary, high dose 
(4.7 to 5.7 MBq/g thyroid tissue) results in higher cure rate 
but most patients would become hypothyroid.51 As such, 20% 
of patients with GH develop hypothyroidism due to natural 
history of the disease.52 The incidence of hypothyroidism 
in patients who achieve euthyroid state following RAI is 
around 3% per annum. Hypothyroidism is preferable to 
hyperthyroidism as it is easier to treat and hyperthyroidism 
is associated with serious morbidities such as atrial fibril-
lation and osteoporosis. Therefore, when treating patients 
with GH with RAI, it is desirable to cure hyperthyroidism 
even if the dose required to achieve this induces iatrogenic 
hypothyroidism.
Fixed versus calculated dose of RAi
In the fixed dose regimens, RAI is administered without 
taking thyroid volume or RAI uptake into consideration. 
Doses ranging from 185 MBq to 550 MBq of RAI are 
commonly administered, with higher doses resulting in higher 
cure rates. In the second approach, a 24-hour uptake of RAI 
is measured before treatment and the dose is calculated based 
on the RAI uptake. Although this approach is individualized 
and ensures optimal dosing and prevents under treatment, 
it requires an additional trip to specialist centers and local 
expertise to measure the uptake. In one randomized controlled 
trial (RCT)53 the success rate as defined by elimination 
of hyperthyroidism was higher (71%) in fixed dose with 
555 MBq compared with 58% in the calculated dose (to 
deliver 100 Gy) arm. However, success rate was inversely 
related to thyroid size in the fixed dose regime. For smaller 
thyroid glands with volumes 15 mL or less, success rate 
was 100% whereas success rate was only 25% when thyroid 
volume was more than 75 mL. In the calculated dose regime, 
success rate was 45% with thyroid volumes 75 mL or more. 
In clinical practice, GH is usually associated with smaller 
thyroid goiters compared with multinodular goiters, and 
therefore a fixed dose regime works well for most patients. 
Our practice is to use a fixed dose treatment with 550 MBq. 
A higher dose (up to 800 MBq) may be required for patients 
with very large goiters with Graves’.
Adjunctive antithyroid drugs with RAi
RAI therapy may result in worsening of thyrotoxic symp-
toms due to an increase in thyroid hormone concentrations 
in the first few weeks after therapy. This may result in 
adverse cardiac outcomes such as atrial fibrillation. Thyroid 
storm is rare but can occur after RAI. Pre-treatment with 
an antithyroid drug restores euthyroidism and may limit 
such adverse outcomes, especially in older patients and in 
those with severe hyperthyroidism. Although this approach 
will not prevent a rise in thyroid hormone levels following 
RAI, it may be argued that the rise of thyroid hormone 
occurs from a lower baseline.54 Similarly, some centers use 
post-treatment antithyroid drugs with RAI. Antithyroid 
medications are started a few days following RAI and are 
continued for 4 to 6 weeks. However it has been suggested 
that adjunctive antithyroid drugs reduce the efficacy of RAI. 
The evidence for this was reviewed in a recently published 
meta-analysis involving 1306 participants in 14 RCTs.55Therapeutics and Clinical Risk Management 2010:6 34
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Antithyroid drugs given in the week before and after RAI 
increased the risk of treatment failure by 28% but lowered 
the risk of hypothyroidism. There were 158/442 events of 
treatment failure in the antithyroid drugs arm compared with 
116/435 in the control arm. In these RCTs CBZ (in 3 RCTS), 
MMI (in 6) and PTU (in 4) were used, while 1 RCT with 
2 treatment arms used PTU and MMI. The dose of RAI used 
varied from 158 and 585 MBq. Further sensitivity analyses 
showed higher risk of treatment failure with fixed dose 
regimens compared with calculated dose methods, pre treat-
ment with antithyroid drugs and higher doses of antithyroid 
drugs. The incidence of atrial fibrillation was 1/660 (0.2%) 
in the adjunctive antithyroid group versus 3/646 (0.5%) in 
the control group with RAI alone. Mortality was reported to 
be higher in the RAI-alone group (6/646, 0.9%) compared 
with 1/660 (0.2%) in the adjunctive antithyroid group. No 
further details were available on increased mortality seen in 
the RAI-alone group. Previous studies have shown increased 
risk of treatment failure with propylthiouracil56 but this was 
not proven in the meta-analyses. The mechanism by which 
antithyroid drugs increase the risk of treatment failure is not 
clear but is thought to be due to decreased iodine uptake in 
the pretreatment group and inhibition of thyroid peroxidase 
involved in cell death after RAI57 in the post-treatment 
group.
Some studies have evaluated the use of lithium as an 
adjunct to RAI to facilitate iodine uptake. In a controlled 
study, lithium carbonate 885 mg daily for 2 weeks with RAI 
increased radiation dose by 40%.58 The role of lithium as 
an adjunct to RAI was evaluated in an RCT involving 110 
newly diagnosed patients with GH. Lithium 900 mg/day 
started on the day of RAI for 6 days increased hyperthy-
roidism cure rate (72% RAI; 83% lithium with RAI) and 
controlled hyperthyroidism earlier with better goiter shrink-
age.59 There were no significant side effects from short-term 
lithium use in this study. However large-scale RCTs are 
required before lithium can be used routinely. At present 
lithium can be considered in patients with larger goiters 
with Graves’, when thyroidectomy is not possible or for 
those patients where RAI failed previously. Glucocorticoids 
have also been evaluated for their role as an adjunct to 
RAI but have not been shown to be effective in improving 
hyperthyroidism cure rates.60
Clinical practice points
Our practice is to render patients euthyroid before RAI with 
antithyroid drugs and we discontinue antithyroid drugs a 
week before planned RAI. We administer 550 MBq RAI as 
a fixed dose and routinely do not restart antithyroid drugs 
following RAI. We use nonselective betablockers in high risk 
patients for about 6 to 8 weeks. If using antithyroid drugs 
after RAI, a minimal effective dose of CBZ/MMI should be 
used starting 3 days after RAI for 4 for 6 weeks with periodic 
monitoring of thyroid hormone levels. Antithyroid drugs 
should be discontinued as soon as free thyroid hormones fall 
below the normal reference range or TSH start rising. Tran-
sient hypothyroidism after RAI is common, especially when 
lower doses of RAI are used. Long-term thyroxine therapy 
is recommended for permanent hypothyroidism and this is 
more likely when higher doses of RAI are used.
Use of recombinant TSH in GH
Recombinant TSH (rhTSH) has been found to increase RAI 
uptake when used for ablating thyroid remnant for patients 
with differentiated thyroid cancer following surgery. Theo-
retically it is possible to use rhTSH in patients with GH to 
increase RAI uptake and ablate thyroid successfully. The use 
of rhTSH has been evaluated in patients with multinodular 
goiter61 with success. However, it is expensive and may 
cause acute worsening of hyperthyroidism. RAI as such has 
more than 80% success rate in Graves’ patients and therefore 
rhTSH is not recommended.
Short- and long-term effects of RAi
Short term
RAI is usually well tolerated but occasionally patients 
experience discomfort in the neck. Rarely patients experi-
ence enlarging goiter, which may lead to airway obstruction. 
High dose steroid therapy usually resolves the inflammatory 
response associated with radiation thyroiditis. A small minor-
ity of patients develop clinically significant worsening of 
hyperthyroidism including thyroid storm.
Elevated thyroid hormones may result in atrial fibrillation 
and adverse cardiac outcomes. Steroid-responsive Hashi-
moto encephalopathy (diffuse encephalopathy and raised 
thyroid antibodies) following RAI has been reported in the 
literature.62 Occasionally RAI can induce GH in patients with 
multinodular goiter.
RAi and the risk of ophthalmopathy
One of the main concerns in using RAI is the risk of devel-
oping or worsening of ophthalmopathy. We published a 
systematic review of 10 RCTs involving 1136 patients com-
paring the effects of RAI on ophthalmopathy with antithyroid 
drugs and surgery.63 Compared with antithyroid drugs, RAI 
increased risk of ophthalmopathy by 4-fold. The use of RAI Therapeutics and Clinical Risk Management 2010:6 35
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also increased the risk of severe ophthalmopathy (defined 
as ophthalmopathy requiring immunosuppression, orbital 
radio therapy, surgery). For patients with mild pre-existing 
ophthalmopathy, prednisolone prophylaxis (0.5 mg/kg body 
weight starting with RAI, continued for 6 weeks after) was 
highly effective in preventing worsening of ophthalmopathy. 
In fact, in some patients ophthalmopathy improved after RAI. 
Adjunctive antithyroid drugs with RAI made no difference 
to the ophthalmopathy outcome. Smoking, high levels of 
pre-treatment T3 (more than twice the upper limit of normal) 
and post-RAI hypothyroidism were associated with increased 
risk of ophthalmopathy on subgroup analysis.
Clinical practice points
The risk of developing ophthalmopathy is around 20% after 
RAI and around 5% after antithyroid drugs; the risk of severe 
ophthalmopathy is around 7% after RAI. We recommend 
appropriate counseling before consenting and strong advice 
to give up smoking. Thyroid functions should be monitored 
regularly after RAI and any hypothyroidism should be treated 
promptly to reduce risk of ophthalmopathy. At least 12 months 
follow-up after RAI is essential as ophthalmopathy usually 
develops or worsens around 6 months after RAI but can occur 
up to 2 years. Use prednisolone 20 to 40 mg daily for 6 weeks 
starting a day before RAI in patients with mild ophthalmopa-
thy and perhaps in smokers and those with high T3 levels.
Long-term effects of RAi
Hypothyroidism is the main long-term effect of RAI. Several 
studies have reported a small but significantly increased risk of 
cardiovascular-64,65 and cancer-related mortality65,66 in patients 
treated with RAI, although it is unknown whether this is due 
to the effect of hyperthyroidism or due to therapy with RAI. 
In the West Midlands study, 67 excess deaths during 15,968 
person-years follow-up after RAI (standardized mortality 
ratio 1.14) were mainly due to cardiovascular causes.64 
Interestingly, this excess mortality was not seen in patients 
who were on thyroxine replacement therapy following RAI. 
Untreated hypothyroidsm following RAI was associated with 
increased risk of ischemic heart disease and death. In a more 
recent Finnish study,65 all-cause mortality was found to be 453 vs 
406 per 10,000 person-years in patients treated with RAI 
and controls, respectively, (rate ratio 1.12). Cerebrovascular 
disease accounted for most deaths but death due to cancer 
was also increased. Gastrointestinal tract cancers, particu-
larly cancer of the stomach and esophagus, were increased 
suggesting a possible local effect of RAI after oral admin-
istration. Mortality increased with increased dose of RAI. 
However, overall mortality was increased only in patients 
with nodular goiter and not in Graves’ patients.
On the contrary, other studies67,68 found no increase in 
overall cancer incidence and mortality but noted a small 
relative increase in thyroid cancer, although the absolute 
risks remained low. The increased incidence of thyroid can-
cer following RAI is mainly in patients with multinodular 
goiter, suggesting risk is largely due to nodular disease itself 
rather than RAI. Athough the long-term follow-up data are 
reassuring in children and adolescents with GH treated with 
RAI,69 we recommend cautious use of RAI in very young 
patients with GH.
Contraindications to RAi
Pregnancy (or immediate desire) and lactation are the major 
contraindications for RAI. Pregnancy must be excluded 
before RAI and women should be strictly advised to defer 
pregnancy for at least 6 months after RAI.70 This is essential 
not only to avoid fetal damage by radiation but also to ensure 
hyperthyroidism is cured and hypothyroidism is promptly 
corrected well before pregnancy to avoid adverse fetal out-
come. Inadvertent RAI treatment before 12 weeks of gesta-
tion is usually not associated with fetal thyroid dysfunction 
but exposure after 12 weeks can ablate fetal thyroid. Early 
pregnancy radiation exposure may result in miscarriage or 
fetal malformations. However, the absolute risks of such 
complications are uncertain and termination of pregnancy 
is not routinely recommended.39
Although evidence is limited, men should be advised 
to defer fathering for at least 4 months after RAI due to 
radiation potentially affecting spermatogenesis.39 Severe 
ophthalmopathy is generally considered to be a contraindi-
cation for RAI.
RAi in special circumstances
Additional precautions will be required for patients with end 
stage renal disease who are undergoing hemodialysis and 
those living in institutions such as prisons. RAI therapy has 
been successfully used in children to treat GH from as early 
as 2 years of age.71
Radiation protection advice for patient  
undergoing RAi
Radiation protection guidelines differ across different coun-
tries, which may influence the choice of therapy. Patients 
who are undergoing RAI should be appropriately counseled 
regarding radiation protection safety. They should be advised 
to avoid close contacts with young children and pregnant Therapeutics and Clinical Risk Management 2010:6 36
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women for 2 weeks after RAI. They should also take 
precautions to keep their clothes and utensils separately for 
the first few days after RAI. They must report to their treating 
centers immediately if they start vomiting or become incon-
tinent of urine within 24 hours after RAI, for safe disposal 
of excreta. Patients should be advised to report to airport 
authorities of their treatment as security alarms could be 
triggered off with radiation.72 It is useful to issue a treatment 
card to patients confirming the date of RAI, the dose and the 
duration for which radiation protections apply.
Other antithyroid agents
Betablockers
Many of the symptoms of hyperthyroidism such as sweat-
ing, anxiety, tremor and palpitations are caused by increased 
sympathetic activity and can be controlled rapidly by beta-
blockers. Propranolol in relatively high doses of over 160 mg 
per day can mildly inhibit conversion of  T4 to T3. Once daily 
betablockers such as atenolol 50 to 100 mg or nadolol 40 to 
80 mg can be used to improve compliance. In the absence of 
contraindications such as asthma, betablockers are used in the 
first few weeks of treating hyperthyroidism while awaiting 
the effect of antithyroid medications. They may also be used 
when antithyroid medications are withdrawn for treating with 
RAI. Rate-limiting calcium channel blockers may be used if 
there are contraindications for betablockers.
iodine and iodine-containing compounds
These are rarely used for the rapid control of hyperthyroid-
ism in the context of thyroid storm or in the preoperative 
preparation for thyroid surgery. Iodide decreases thyroid 
hormone synthesis by blocking iodide oxidation and organi-
fication – the Wolff–Chaikoff effect. It also inhibits thyro-
globulin proteolysis and release of T4 and T3. The effect is 
rapid and pronounced but lasts for only a few weeks with a 
potential for subsequent deterioration. Iodide decreases the 
vascularity of the thyroid but in one controlled study had no 
significant influence on blood loss or perioperative course.73 
It can be given as Lugol’s solution (8 mg of saturated iodide 
per drop) 3 to 5 drops 3 times a day or as a saturated solu-
tion of potassium iodide (SSKI, 50 ng of iodide per drop) 
1 drop 3 times a day. Oral cholecystographic agents (sodium 
iopanoate and sodium ipodate) have also been used for rap-
idly lowering thyroid hormone levels in combination with 
MMI74 and may be useful in thyroid storm.
Lithium
Lithium has a role in inhibiting thyroid hormone synthesis 
and release. Lithium can rarely be used in patients intolerant 
of thionamides. It has been shown to reduce the thyroid hor-
mone increase after thionamide withdrawal and RAI therapy 
in Graves’ disease as discussed above.
Potassium perchlorate
This is a competitive inhibitor of iodide transport but is rarely 
used due to its side effects, particularly the risk of aplastic 
anemia with long-term use. It may be used in the context of 
amiodarone-induced thyrotoxicosis or while awaiting RAI 
in patients allergic to thionamides.
Cholestyramine
Cholestyramine decreases the enterohepatic reabsorbtion 
of thyroid hormones. Thyrotoxic patients have an abnormal 
increase of thyroid hormones in their enterohepatic circula-
tion. Cholestyramine used in combination with PTU or MMI 
brought about a more rapid decline of thyroid hormones 
during the first month of antithyroid therapy.75,76
Newer immunomodulatory agents
Graves’ disease is an autoimmune B-cell mediated condition 
in which TSH receptor antibodies (TRAb) play an important 
role in the pathogenesis. A few agents are being investigated 
but the only agent that has entered phase II clinical stud-
ies is rituximab (RTX). This is an anti-CD20 monoclonal 
antibody which causes B cell depletion in the circulation as 
well as in target organs such as the thyroid. RTX was the first 
monoclonal antibody used in the treatment of non-Hodgkin’s 
lymphoma. This has also been used in various autoimmune 
diseases including rheumatoid arthritis. Two small studies 
have shown a positive benefit in the clinical course in Graves’ 
ophthalmopathy without affecting the thyroid function.77,78 
The effects on the hyperthyroidism in Graves’ disease are 
less promising. In one controlled study 4 of 10 patients 
receiving RTX remained in remission 1 year after therapy 
while all 10 patients not receiving RTX relapsed.79 In a further 
phase II study of 13 patients with relapsing Graves’ disease, 
9 patients given 2 doses of RTX 1000 mg intravenously with 
a 2-week interval were euthyroid at a median of 18 months 
of follow-up while 4 patients who had initial high thyroid 
hormone levels failed to respond and needed subsequent 
RAI therapy.80 Due to the limited experience and costs of 
these agents, further studies are needed before these agents 
are considered as possible therapies in GH.
Surgery and interventional therapies  
for GH
Thyroid surgery is an option that may be used particularly 
as an alternative to RAI during recurrent hyperthyroidism Therapeutics and Clinical Risk Management 2010:6 37
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Figure 1 evidence-informed pragmatic choices of antithyroid therapy.
Abbreviations: ATD, antithyroid drugs; RAi, radioiodine.
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or in uncontrolled hyperthyroidism despite high doses of 
antithyroid drugs. This may also be considered during poorly 
controlled hyperthyroidism during pregnancy or if there is a 
suspicion of a coexistent malignant thyroid nodule. Patients 
with large goiters particularly with compressive symptoms, 
with poor compliance with antithyroid drugs, or with severe 
ophthalmopathy would also be suitable candidates for a 
surgical approach.81 There has been some debate about the 
extent of surgery – total versus subtotal thyroidectomy. 
There has been 1 meta-analysis82 on these approaches. In 
35 studies involving over 7000 patients, total thyroidectomy 
was equally safe, with 0.9% recurrent laryngeal nerve 
palsy (RLN), 0.9% permanent hypoparathyroidism and no 
recurrent disease. Subtotal thyroidectomy resulted in 0.7% 
RLN palsy, 1.0% incidence of hypoparathyroidism and 
7.9% recurrent or persistent disease. If surgery was being 
considered for the therapy of Graves’ disease, total thyroid-
ectomy would be our preferred option. This would also be 
preferred in the presence of mild Graves’ ophthalmopathy. 
Surgery may also induce a rise in thyroid receptor antibod-
ies and thyroid hormones, and steroid cover may need to be 
considered for those with significant ophthalmopathy. One 
randomized study suggested that in patients with ophthal-
mopathy on glucocorticoids, total thyroid ablation (surgery 
followed by RAI) had a better outcome in relation to the 
progression of the ophthalmopathy than total thyroidectomy 
alone.83 Selective arteriography, followed by embolization 
of the thyroid arteries was a novel technique reported in 
1 series, 14 of 22 patients with Graves’ disease becoming 
euthyroid with no additional therapy.84
Treatment of complications of GH
Graves’ ophthalmopathy
The main aim of treatment of Graves’ ophthalmopathy 
is to restore euthyroidism promptly since both hyper and 
hypothyroidism aggravates ophthalmopathy. Patients should 
be strongly advised to give up smoking. In addition, local 
measures such as lubricants help to relieve symptoms. 
Prisms may help diplopia. Moderate to severe cases should 
be referred to ophthalmologists for specialist management. 
A detailed discussion of the treatment of Graves’ ophthal-
mopathy is beyond the scope of this article.
Graves’ dermopathy
Treatment of dermopathy associated with Graves’ disease is 
unsatisfactory especially in its chronic phase. Topical steroids 
with occlusive dressing or systemic glucocorticoids may help 
recent onset of dermopathy.
Choice of therapy (Figure 1)
The three main choices in the form of surgery, RAI and 
antithyroid drugs have remained unchanged over several 
decades. Various factors influence the choice of treatment, 
which include patient and physician preference, availability 
of surgical expertise, concerns on radiation or the difficulties 
in complying with radiation protection guidance, concerns on 
side effects of medications, predictors of relapsing disease and 
cost. RAI is the most cost-effective treatment when consider-
ing the cost of surgery and the high relapse rates.85 However 
in the European context most patients would prefer to have at 
least one course of antithyroid medications before considering 
RAI. Our approach would be to discuss all three possibilities at 
the outset. Most patients would choose antithyroid drugs and 
we would use the titration regimen for 12 to 18 months. We 
would attempt to be more persuasive about RAI at the point 
of the second relapse. Women may also be influenced by the 
fact that radiation protection may be technically challenging 
once they have had children, and if their hyperthyroidism is 
tending to have relapses they may well wish to consider a 
definitive route if they have no immediate plans for pregnancy. 
If RAI is chosen we would be using a fixed dose and consider 
steroid cover only if there was evidence of mild ophthalmopa-
thy. We would be encouraging modifying risk factors such as 
smoking at every opportunity. Following RAI we would aim 
to pick up the hypothyroidism and treat this without delay. In 
the proportion who refuse RAI we would give another 12- to 
18-month course of antithyroid drugs and in some with the 
risk of recurrent hyperthyroidism (cardiac failure, atrial fibril-
lation or elderly) we would consider a much longer course of 
low dose CBZ. The patient would also have the opportunity 
to choose surgery particularly if they have a large goitre or 
have significant thyroid eye disease.
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